<DOC>
	<DOCNO>NCT00035100</DOCNO>
	<brief_summary>This study examine whether new investigational drug EPO906 , give intravenous infusion ( IV directly vein ) , effective shrinking tumor prevent growth cell cause ovarian , fallopian , peritoneal cancer . Recruitment United States complete study still enrol country .</brief_summary>
	<brief_title>EPO906 Therapy Patients With Advanced Ovarian , Primary Fallopian , Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>The following patient may eligible study : Histologically cytologically document evidence ovarian , primary Fallopian primary peritoneal cancer least one measurable lesion ( previous radiation treatment , target lesion must demonstrate progression since radiation ) Must life expectancy great three ( 3 ) month Prior failure respond follow frontline treatment taxane platinum ( combination therapy ) may eligible . The following patient eligible study : Patients radiation therapy chemotherapy within last four week Patients chemotherapy contain taxane platinum disease Patients borderline ovarian macropapillary tumor Patients unresolved bowel obstruction Patients symptomatic CNS metastasis leptomeningeal involvement Patients peripheral neuropathy unresolved diarrhea great Grade 1 Patients severe cardiac insufficiency Patients take Coumadin warfarincontaining agent exception low dose Coumadin ( 1 mg less ) maintenance indwell line port History another malignancy within 5 year prior study entry except curatively treat nonmelanoma skin cancer cervical cancer situ Patients active suspect acute chronic uncontrolled infection include abcesses fistulae HIV+ patient Pregnant lactating female .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ovarian</keyword>
	<keyword>ovary</keyword>
	<keyword>peritoneal cancer</keyword>
	<keyword>fallopian cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>tumour</keyword>
	<keyword>neoplasm</keyword>
	<keyword>carcinoma</keyword>
	<keyword>intravenous</keyword>
	<keyword>epothilone</keyword>
</DOC>